RemeGen Co., Ltd., a biopharmaceutical company, engages in the discovery, development, and commercialization of biologics for the treatment of autoimmune, oncology, and ophthalmic diseases with unmet medical needs in Mainland China and the United States. The company offers Telitacicept (RC18) for use in the treatment of systemic lupus erythematosus an autoimmune disease and Disitamab Vedotin (RC48) for use in the treatment of various cancers. Its products in various stages of development include RC18, which is under phase III clinical trials for the treatment of neuromyelitis optica spectrum disorder and rheumatoid arthritis, and phase II clinical trials for the treatment of IgA nephritis, Sjögren's syndrome, multiple sclerosis, and myasthenia gravis; RC28, which has completed Phase 1 clinical trials for use in the treatment of wet age-related macular degeneration, diabetic macular edema, and diabetic retinopathy; RC98, a PD-L1 monoclonal antibody for the treatment of solid tumors and is under Phase I clinical trial; RC88, which is in Phase 1 clinical trials for use in the treatment of mesothelioma, bile duct carcinoma, pancreatic cancer, ovarian carcinoma, lung adenocarcinoma, and other solid tumors; and RC108 that is in Phase 1 clinical trials to treat various solid tumors. In addition, the company's products under pre-clinical development include RC118, RC138, RC148, RC158, RC168, RC178, RC188, and RC198 to treat various solid tumors; and RC218 and RC228 to treat ophthalmopathy. RemeGen Co., Ltd. was incorporated in 2008 and is headquartered in Yantai, the People's Republic of China.
| 1.5 | |
| 1.5 | |
| - | |
| 1.5 | |
| 1.5 | |
| 1.5-4.1 | |
| 1 555 M | |
| 190 M | |
| 1 404 M | |
| -0.1108 | |
| 0.363 |
No long-term obligations. The minimum period is one month only. No wait. You get an API key with instructions in a few seconds right after subscription.
As global markets experience fluctuations and major indices show mixed performance, the Hong Kong market continues to attract attention from investors looking for growth opportunities. In this environ...
As global markets respond positively to anticipated interest rate cuts in the U.S., the Hong Kong market has also shown resilience, particularly in its tech sector. With this favorable backdrop, ident...
Our 24/7 support would be happy to assist you via chat or email:
support@eodhistoricaldata.comVisit also:
